- CEO
- Hai Run Wang
- Full Time Employees
- 2,843
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- No. 1 Industrial Avenue Wuzhou GG China 543000
- IPO Date
- Nov 30, 2000
- Business
- Guangxi Wuzhou Zhongheng Group Co., Ltd. manufactures and distributes pharmaceuticals, traditional Chinese medicines, health products, and daily consumer goods; its core business encompasses pharmaceutical manufacturing, health consumption, research and development of traditional Chinese medicine resources, cosmetics, and pharmaceutical distribution. The company produces injectable thrombotron (freeze-dried), Chinese dumpling pills, gout tablets, shedan chuanbei liquid, Kun Yue'an, clam oral liquid, xueshuantong for shooting, zhonghua dieda pills, angong niuhuang pills, fuyanjie capsules, jieshitong tablets, yanjianning tablets, and sodium fluorescein injection under brands including Zhonghua, Chenzhong, and Zhongheng, covering cardiovascular, cerebrovascular, neurology, endocrinology, orthopedics, ophthalmology, gynecology, pediatrics, respiratory, urinary system, antineoplastic drugs, digestive drugs, parenteral nutritional drugs, anti-infectives, and large infusions; it also offers chemical preparations and raw materials, traditional health products such as turtle jelly paste and derivatives, turtle jelly, turtle jelly powder, Liubao tea and drinks, instant porridge, beverages, solid drinks, innovative traditional Chinese medicines, high-end generic pharmaceuticals, health foods, daily necessities, and consumer care items including 37 targeted toothpaste, smart electric toothbrushes, bio-enzyme mouthwashes, detergents, laundry detergent, soap, and shampoo under Field Seven, Tianqi Baby, Jianguo, Easy Butler, and Pure Cotton Era brands. Founded in 1993 and listed on the Shanghai Stock Exchange in 2000 under ticker 600252.SS, the company is headquartered at No. 1 Industrial Avenue, Wuzhou Industrial Park, Wuzhou, Guangxi Zhuang Autonomous Region, China, with primary operations in China; its subsidiary Guangxi Wuzhou Pharmaceutical (Group) Co., Ltd. serves as a leading chain enterprise in Guangxi, and the firm ranks among China's top 100 pharmaceutical industrial and traditional Chinese medicine enterprises while being controlled by Guangxi Investment Group Co., Ltd. Recent developments include Guangxi Investment Group Financial Holdings Company Limited's completion of a CNY 4.1 billion acquisition of a 26.89% stake from Guangxi Investment Group Co., Ltd. on October 31, 2025, following securities transfer registration confirmation; the company also announced a CNY 500 million equity buyback in January 2025, a subsidiary's selection for traditional Chinese medicine procurement in February 2025, and supplementary approval for an antibiotic product. Additional activities span health food production, pharmaceutical distribution, project investment and management, real estate development and operation, and cosmetics.